Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to six new employees under its 2024 Inducement Plan. The awards consist of 23,800 restricted stock units (RSUs) of Intellia's common stock.

The RSUs will vest in three equal installments on July 1 of 2026, 2027, and 2028, subject to continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics announced positive three-year data from its Phase 1 trial of lonvoguran ziclumeran (lonvo-z) for Hereditary Angioedema (HAE). The groundbreaking results showed a 98% mean reduction in monthly HAE attacks across all 10 patients after a single dose, with patients remaining attack-free and treatment-free for a median of 23 months. The CRISPR-based therapy demonstrated a favorable safety profile, with only mild infusion-related reactions reported. The company's Phase 3 HAELO trial has completed screening ahead of schedule, with over 50% of patients screened from U.S. sites. Intellia plans to submit a biologics license application in 2026 and aims for a U.S. launch in 2027. The therapy shows promise as the first potential one-time treatment for HAE patients, offering freedom from both attacks and chronic therapy management.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company, announced the granting of inducement awards to six new employees on June 1, 2025. The awards, issued under Intellia's 2024 Inducement Plan, consist of time-based restricted stock units (RSUs) for 33,600 shares of common stock. The RSUs will vest in three equal installments on June 1 of 2026, 2027, and 2028, contingent on continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) reported positive two-year follow-up data from its Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy. Key findings include:

The treatment demonstrated 90% mean serum TTR reduction by Day 28 in patients receiving doses ≥0.3 mg/kg (n=33), with levels remaining stable for at least 24 months. Among 18 patients evaluated at 24 months, 14 showed clinically meaningful improvement of ≥4 points in mNIS+7 scores, including 5 of 6 patients previously progressing on patisiran.

The drug showed a favorable safety profile with only mild to moderate infusion-related reactions reported. The company continues enrollment in MAGNITUDE-2 trial, aiming for potential BLA submission by 2028.

Intellia Therapeutics (NASDAQ:NTLA) reported its Q1 2025 financial results and clinical progress. The company is advancing three key Phase 3 trials: HAELO study for hereditary angioedema (HAE), MAGNITUDE-2 for hereditary ATTR amyloidosis with polyneuropathy, and MAGNITUDE for ATTR with cardiomyopathy. Financial highlights include a cash position of $707.1M expected to fund operations into H1 2027, though this represents a decrease from $861.7M in Q4 2024. Q1 revenue was $16.6M, down from $28.9M year-over-year, with a net loss of $114.3M. Clinical milestones include completing HAELO study enrollment in Q3 2025, presenting additional NTLA-2002 Phase 1 data at EAACI Congress in June, and sharing longer-term data for both ATTR-CM and ATTRv-PN patients in H2 2025. The company's lead programs utilize CRISPR-based gene editing technology delivered through lipid nanoparticles.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to eight new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) for 69,600 shares of common stock. The RSUs will vest in three equal installments on May 1 of 2026, 2027, and 2028, contingent on continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducement for employment.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has scheduled its first quarter 2025 earnings conference call for May 8, 2025, at 8 a.m. ET. The company will discuss financial results and operational highlights during the call.

U.S. participants can join by dialing 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will be available, and a replay can be accessed through Intellia's website after 12 p.m. ET on the same day.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to three new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) totaling 8,400 shares of common stock.

The RSUs will vest in three equal installments on April 1 of 2026, 2027, and 2028, contingent upon continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) has announced the dosing of the first patient in MAGNITUDE-2, a global Phase 3 trial of nexiguran ziclumeran (nex-z) for treating hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). This gene editing-based treatment aims to provide a one-time solution for this progressive, debilitating disease.

The trial builds on promising Phase 1 data that demonstrated nex-z's ability to achieve rapid, deep, and durable reduction in serum TTR levels with a single dose. The company plans to present extended Phase 1 data for both polyneuropathy and cardiomyopathy applications later this year, with a target to submit a biologics licensing application (BLA) for ATTRv-PN by 2028.